A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 18 - 20 January 2018, vol.36, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Volume: 36
- Doi Number: 10.1200/jco.2018.36.4_suppl.26
- City: San-Francisco
- Country: Costa Rica
- Hacettepe University Affiliated: Yes